Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sevasemten - Edgewise Therapeutics

Next Previous
Drug Profile

Sevasemten - Edgewise Therapeutics

Alternative Names: EDG-5506

Latest Information Update: 20 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Edgewise Therapeutics
  • Class Ethers; Fluorinated hydrocarbons; Ketones; Pyridazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Creatine kinase inhibitors; Myosin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Duchenne muscular dystrophy
  • Phase II Glycogen storage disease type V; Limb girdle muscular dystrophies

Most Recent Events

  • 07 Aug 2025 Edgewise Therapeutics plans a phase-III trial for Duchenne muscular dystrophy (PO) in 2026
  • 21 Jul 2025 Edgewise Therapeutics plans a phase II trial for Becker muscular dystrophy, McArdle disease or Limb girdle muscular dystrophies in Denmark (PO) (CTIS2022-500215-39-00)
  • 26 Jun 2025 Edgewise Therapeutics completes a successful Type C meeting with the US FDA for registration path for Duchenne muscular dystrophy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top